ClinicaliQ Trial Snapshot
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting • Phase III • NCT07623200.
- INCA033989 is tested against standard treatment in patients with essential thrombocythemia and CALR mutations who've had previous cytoreductive therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy. Conditions: Essential Thrombocythemia Interventions: INCA033989, Best Available Treatment Lead Sponsor: Incyte Corporation Planned Enrollment: 426 participants